Saturday 17 October 2026
Export STOK’s income statement to Excel — free account
Stoke Therapeutics, Inc.
STOK Healthcare Biotechnology
Stoke Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $184.4 million, up 404.5% from fiscal 2024. In the quarter to June 2026, revenue fell 32.5%, EPS fell 132.5% and free cash flow fell 129.0%, each against the same quarter a year earlier.
24.17
0.44
−1.79%
Follow STOK
Stoke Therapeutics, Inc. (STOK) P/E ratio
Stoke Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 49.4× (October 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 32.6× | 158.81% |
| 14 more quarters | Free account |
Against its own ten years
Low 0.0×
High 49.4×
Ten-year median
0.0×
Current reading's percentile
81
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| OCUL Ocular Therapeutix, Inc. compare | n/m |
| ZBIO Zenas BioPharma, Inc. compare | n/m |
| QURE uniQure N.V. compare | n/m |
| STOK Stoke Therapeutics, Inc. | n/m |
| ABSI Absci Corporation compare | n/m |
| MAZE Maze Therapeutics, Inc. compare | n/m |
| NTLA Intellia Therapeutics, Inc. compare | n/m |
| KRSA Korsana Biosciences, Inc. compare | n/m |
| GPCR Structure Therapeutics Inc. Sponsored ADR compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)